|
国际站:Nemonoxacin
CAS:378746-64-6
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Nemonoxacin (TG-873870) 是一种口服有效的强效广谱抗生素。Nemonoxacin 对不同种类的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌均具有较好的抑制活性。Nemonoxacin 可用于细菌感染和社区获得性肺炎的研究。
体外:Nemonoxacin (0-5.51 µM; 24 h) shows good antibacterial activity in vitro[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内:Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates[2]. Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CD-1 ICR mice (18-22 g; mouse systemic infection model)[2]. Dosage: 1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections) Administration: Oral administration; 15 min and 6 h after infection Result: Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively. Animal Model: CD-1 ICR mice (18-22 g; mouse pulmonary infection model)[2]. Dosage: 2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607) Administration: Oral administration; 6, 12 and 24 h after infection Result: Significantly decreased colony counts in vivo. Clinical Trial
参考文献:[1]. Adam HJ, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20.[2]. Li CR, et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother. 2010 Nov;65(11):2411-5.[3]. Lauderdale TL, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-7-10 15:25
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社